What does this research mean for the field?

Q: What does this research mean for the field?

Initiation of GLP-1 receptor agonists in patients with concurrent COPD and type 2 diabetes is associated with a significant reduction in COPD exacerbations and oral corticosteroid use. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

March 3, 2026Open Access

The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study

Key Points

Patients treated with GLP-1 receptor agonists had significantly fewer COPD exacerbations, leading to lower rates of health resource utilization.
In the follow-up year, the adjusted incidence rate ratio for exacerbations was 0.84, indicating a meaningful reduction compared to matched controls.

Structured PICO

Does initiation of GLP-1 RAs reduce COPD exacerbations in patients aged ≥ 40 years with COPD and T2D?

Population

4,479 matched patients aged ≥ 40 years with chronic obstructive pulmonary disease (COPD) and type 2 diabetes (T2D).

Intervention

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a class

Comparator

GLP-1 naïve controls matched 1:1 based on age, sex, smoking status, COPD treatment (LABA/LAMA/ICS), and exacerbation history

Outcome

Number of COPD exacerbations during the 12 months following the index datehard clinical

In patients with comorbid COPD and T2D, initiation of GLP-1 RAs is associated with a significant reduction in COPD exacerbations and oral corticosteroid use over 12 months.

Abstract

Introduction: There is limited evidence on the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with chronic obstructive pulmonary disease (COPD). Material and Methods: We conducted a retrospective matched cohort study including patients aged ≥ 40 years with COPD and T2D. Patients initiating GLP-1 RAs were matched 1:1 with GLP-1 naïve controls based on age, sex, smoking status, COPD treatment (LABA/LAMA/ICS), and exacerbation history. The index date was defined as the first GLP-1 RA prescription, control’s index date was a COPD consultation within 186 days of matched patient index. The primary outcome was the number of COPD exacerbations during the 12 months following the index date. Secondary outcomes included oral corticosteroid (OCS) prescriptions and hospital resource utilization (HCRU). Poisson regression models adjusted for BMI and other confounders were used to estimate incidence rate ratios (IRR). Results: A total of 4479 matched patients were included. There were no significant differences between groups in exacerbation rates or OCS use in the year prior to the index date. During follow-up, patients treated with GLP-1 RAs had significantly fewer exacerbations (adjusted IRR aIRR 0.84, 95% CI: 0.79– 0.89) and fewer OCS prescriptions (aIRR 0.86, 95% CI: 0.77– 0.95) compared with controls. A significant delay in time to first OCS prescription was also observed. Conclusion: In this real-world cohort, initiation of GLP-1 RA treatment in patients with COPD and T2D was associated with lower COPD exacerbations and OCS use. These findings suggest a potential role for GLP-1 RAs in modifying the course of COPD in this comorbid population, warranting randomised trials. Keywords: COPD, obesity, COPD outcomes, GLP-1 RA

Bookmark

View Full Paper